Commentary on 'response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer'

摘要

We appreciate the insightful comments from Bellati et al. and welcome the opportunity to discuss and explain some findings of our article further. They present a letter to the editor entitled "Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer" and consider that the results of Yildirim et al. would be highly informative if compared the prognosis between primary surgery and neoadjuvant chemotherapy (NACT) plus interval cytoreductive surgery. In this context, there are many large sampled studies evaluating the prognostic consequences between women treated with primary cytoreductive surgery followed by platinum-based chemotherapy and NACT followed by interval surgical cytoreduction [1-3]. First of all, the aim and different side of our study were to identify disease and treatment-related predictors of response to NACT in 35 patients with advanced stage epithelial ovarian cancer (EOC) who were not optimally cytoreductable.